Evidence map›Paper›PMID 35484621›Full record

ArticleBMC pulmonary medicine2022

Likely uptake of a future a lung cancer screening programme in Hodgkin lymphoma survivors: a questionnaire study.

Rachel Broadbent, Christopher J Armitage, Philip Crosbie, John Radford, Kim Linton

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Rachel BroadbentDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. rachel.broadbent-2@postgrad.manchester.ac.uk.
Christopher J ArmitageNIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester, UK.
Philip CrosbieDivision of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, M20 4BX, UK.
John RadfordManchester Cancer Research Centre, Wilmslow Road, Manchester, M20 4QL, UK.
Kim LintonManchester Cancer Research Centre, Wilmslow Road, Manchester, M20 4QL, UK.
University of Manchester · GBCancer Research UK Manchester CentreCancer Research UK Manchester Institute · GBManchester University NHS Foundation Trust · GB

Funding

NIHR Greater Manchester Patient Safety Translational Research Centre PSTRC-2016-003
6 · The paper itself

Abstract

backgroundMany Hodgkin lymphoma (HL) survivors are at increased risk of subsequent malignant neoplasms (SMN), including lung cancer, due to previous treatment for HL. Lung cancer screening (LCS) detects early-stage lung cancers in ever smokers but HL survivors without a heavy smoking history are ineligible for screening. There is a rationale to develop a targeted LCS. The aim of this study was to investigate levels of willingness to undergo LCS in HL survivors, and to identify the psycho-social factors associated with screening hesitancy.

methodsA postal questionnaire was sent to 281 HL survivors registered in a long-term follow-up database and at increased risk of SMNs. Demographic, lung cancer risk factors, psycho-social and LCS belief variables were measured. Multivariable logistic regression analysis was performed to determine the factors associated with lung cancer screening hesitancy, defined as those who would 'probably' or 'probably not' participate.

resultsThe response rate to the questionnaire was 58% (n = 165). Participants were more likely to be female, older and living in a less deprived area than non-participants. Uptake (at any time) of breast and bowel cancer screening among those previously invited was 99% and 77% respectively. 159 participants were at excess risk of lung cancer. The following results refer to these 159. Around half perceived themselves to be at greater risk of lung cancer than their peers. Only 6% were eligible for lung cancer screening pilots aimed at ever smokers in the UK. 98% indicated they would probably or definitely participate in LCS were it available. Psycho-social variables associated with LCS hesitancy on multivariable analysis were male gender (OR 5.94 CI 1.64-21.44, p < 0.01), living in an area with a high index of multiple deprivation decile (deciles 6-10) (OR 8.22 CI 1.59-42.58, p < 0.05) and lower levels of self-efficacy (OR 1.64 CI 1.30-2.08 p < 0.01).

conclusionHL survivors responding to this survey were willing to participate in a future LCS programme but there was some hesitancy. A future LCS trial for HL survivors should consider the factors associated with screening hesitancy in order to minimise barriers to participation.

Indexed as

Hodgkin DiseaseLung NeoplasmsEarly Detection of CancerFemaleHumansMaleRisk FactorsSurveys and QuestionnairesSurvivorsHodgkin lymphomaLung cancerScreeningWillingness

Identifiers

PMID35484621
PMCPMC9052526
OpenAlexW4225303380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.